[Decreasing Susceptibility of MRSA to Daptomycin During the Course of Treatment]

Kansenshogaku Zasshi. 2016 Jul;90(4):493-8.
[Article in Japanese]

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) with decreased susceptibility to daptomycin (DAP) were isolated from 4 patients receiving DAP from November 2013 to May 2014. These patients were treated with DAP for more than 7 days in all the cases. The pulsed-field gel electrophoresis (PFGE) patterns for MRSA isolates recovered from each patient pre- and post-DAP therapy were identical. Sequencing of mprF detected 2 amino acid substitutions (T345I or L826F) in 2 of the isolates. These results suggest that in vivo MRSA was resistant to DAP during DAP therapy. Furthermore, the MICs for DAP can vary by±1 dilution depending on the susceptibility test. When testing DAP susceptibility, there is a need to monitor reproducibility using different susceptibility tests, including the CLSI method.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Daptomycin / therapeutic use*
  • Electrophoresis, Gel, Pulsed-Field
  • Female
  • Gene Expression Regulation, Bacterial
  • Humans
  • Male
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Microbial Sensitivity Tests
  • Middle Aged
  • Staphylococcal Infections / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Daptomycin